CFO Herb Cross Resigns; CEO Takes Interim Finance Role
JSPR sits 99% above its 52-week low of $0.315 on light trading volume (0.2× avg).
Summary
Jasper Therapeutics' CFO resigned effective October 9, 2026. The CEO and other executives will fill the finance roles on an interim basis.
Key Events · Executive and Board Changes · JSPR
-
CFO Resignation
Herb Cross resigned as CFO, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary effective October 9, 2026, to pursue other professional endeavors.
-
Interim Leadership Appointments
CEO Jeet Mahal appointed interim Principal Financial Officer; VP Finance Rick Ruiz appointed interim Principal Accounting Officer; COO Matthew Ros appointed interim Corporate Secretary, each effective upon Cross's resignation.
-
Compensation Terms
Rick Ruiz continues at a $364,000 annual base salary with equity plan eligibility; no equity awards were granted in connection with the promotion.
-
Context: Financial Distress
The departure occurs amid going-concern doubts, a Nasdaq minimum equity deficiency with a November 30 deadline, and a September 30 special meeting to vote on a reverse stock split.
Analysis · JSPR · Life Sciences
CFO Herb Cross resigned effective October 9, 2026, to pursue other opportunities. CEO Jeet Mahal steps in as interim Principal Financial Officer, with VP Finance Rick Ruiz as interim Principal Accounting Officer and COO Matthew Ros as interim Corporate Secretary. The departure of the CFO during a period of going-concern doubts, Nasdaq delisting risk, and an upcoming reverse-split vote adds leadership uncertainty at a critical juncture.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $0.32 to $2.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.